Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + cisplatin for malignant pleural effusion and ascites from lung cancer
ChiCTR2100048959Phase 4Completed
- Sponsor
- BenQ Medical Center
- Start
- Jun 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bevacizumab and cisplatin in malignant pleural effusion (MPE), malignant ascites and bronchial carcinoma (2 arms), sponsored by BenQ Medical Center. Primary endpoint: Quality of life score. Started Jun 2018; status: completed.
02
Drugs
bevacizumabcisplatin
03
Conditions
malignant pleural effusion (MPE)malignant ascitesbronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2100048959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048959.